Actinic Keratoses Treatment Guidelines

First-Line Topical Medications

The American Academy of Dermatology strongly recommends field treatment with topical 5-FU for actinic keratoses based on moderate-quality evidence, with 5-FU being particularly effective when combined with calcipotriol for enhanced clearance 1, 2
The American Academy of Dermatology strongly recommends field treatment with imiquimod based on moderate-to-high quality evidence 1, 6
5% 5-FU cream achieves 38% complete clearance at 6 months versus 17% with placebo (P<0.01) 1
0.5% 5-FU cream demonstrates 67% reduction in lesion count and is better tolerated than 5% formulation while maintaining comparable efficacy 1, 2
Enhanced regimen: 5-FU combined with calcipotriol for 4 consecutive days produces superior results—87.8% mean reduction on face, 76.4% on scalp, and 27% complete clearance versus 0% with 5-FU alone (P<0.0001) 5, 6
5% imiquimod cream: Apply 2-3 times weekly for 4-16 weeks, with complete clearance rates: 29.3% (9-24 doses) to 40.8% (32-56 doses) 1, 2, 6
Adverse effects of imiquimod: Severe local skin reactions occur in 20.6-41.5% of patients; influenza-like symptoms in 3.7%; discontinuation due to adverse events in only 0.6-1.2% 6

The American Academy of Dermatology conditionally recommends diclofenac based on lower quality evidence than 5-FU or imiquimod, with 32% complete clearance at 8 weeks post-treatment 1, 2, 4
Diclofenac 3% gel: Apply 2.5-3% diclofenac in hyaluronic acid gel twice daily for 60-90 days, with a black box warning for NSAIDs carrying cardiovascular and gastrointestinal side-effect warnings 1, 2, 7

5-FU plus cryosurgery: Conditionally recommended over cryosurgery alone (moderate-quality evidence) 1, 2
Imiquimod plus cryosurgery: Conditionally recommended over cryosurgery alone (low-quality evidence) 1, 2
Diclofenac plus cryosurgery: Conditionally recommended AGAINST—no added benefit 1, 2

Patient counseling is critical: Over 90% of patients treated with 0.5% 5-FU/salicylic acid experience irritation 1
Avoid poor healing sites: Use extreme caution applying 5-FU to lower legs due to ulceration risk; consider supervision and compression bandaging 8, 3
Ingenol mebutate withdrawn: Market authorization was withdrawn in the European Union after data showed 3-times higher skin cancer incidence at 3 years (6.3%) compared to imiquimod (2%) 6
Maintenance therapy: Actinic keratosis is a chronic disease requiring ongoing management, with patients educated about self-care, sun protection, and monitoring for new lesions or transformation to squamous cell carcinoma 8, 9